The FDA has approved upadacitinib, a Janus kinase inhibitor, for the treatment of giant cell arteritis in adults-marking the ...

rinvoq成为欧盟、冰岛、列支敦士登以及挪威目前首个且唯一获批用于治疗gca成年患者的口服jak抑制剂。 艾伯维：欧盟委员会批准RINVOQ用于治疗成人GCA ...

AbbVie announced the US Food and Drug Administration (FDA) has approved Rinvoq (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis (GCA). This comes after the ...

AbbVie’s Rinvoq (upadacitinib) has been approved by the US Food and Drug Administration (FDA) to treat adults with giant cell ...

智通财经APP获悉，艾伯维(ABBV.US)周五宣布上调2025年盈利预期，得益于其新型免疫药物Skyrizi和Rinvoq的强劲销售表现，公司第一季度业绩超出华尔街预期。

The US Food and Drug Administration (FDA) has granted approval for AbbVie’s 15mg Rinvoq (upadacitinib) to treat adults with ...

Upadacitinib (RINVOQ) is being studied in Phase 3 clinical trials for alopecia areata, hidradenitis suppurativa, Takayasu arteritis, systemic lupus erythematosus, and vitiligo.5-9 It is not ...

Rinvoq offers a more convenient option for patients ... It is being studied in phase 3 trials for alopecia areata, hidradenitis suppurativa, Takayasu arteritis, systemic lupus erythematosus ...

NORTH CHICAGO, Ill., April 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ ® (upadacitinib), 15 mg, once daily ...

(RTTNews) - AbbVie (ABBV) Tuesday said the U.S. Food and Drug Administration (FDA) has approved Rinvoq for the treatment of adults with giant cell arteritis (GCA). GCA is an autoimmune disease ...